A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

PHASE3RecruitingINTERVENTIONAL

Enrollment

290

Participants

Timeline

Start Date

April 6, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

January 31, 2027

Conditions

Advanced or Metastatic Urothelium Cancer

Interventions

DRUG

MRG002

Administrated intravenously

DRUG

Docetaxel Injection

Administrated intravenously

DRUG

Paclitaxel Injection

Administrated intravenously

DRUG

Gemcitabine Hydrochloride for Injection

Administrated intravenously

DRUG

Pemetrexed Disodium Injection

Administrated intravenously

Trial Locations (1)

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

Shanghai Miracogen Inc.

INDUSTRY